Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina
ConclusionSacubitril/valsartan is a cost-effective treatment in HFrEF using local inputs that considered the financial instability. For both payers considered the cost per QALY gained are under the cost-effectiveness threshold considered.
Source: Health Economics Review - Category: International Medicine & Public Health Source Type: research
More News: Argentina Health | Cardiology | Diovan | Economics | Enalapril | Health Management | Heart | Heart Failure | International Medicine & Public Health